NASDAQ:XOMA - XOMA Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $13.76 -0.67 (-4.64 %) (As of 03/20/2019 04:00 PM ET)Previous Close$14.43Today's Range$13.71 - $14.5752-Week Range$11.02 - $25.99Volume67,395 shsAverage Volume52,826 shsMarket Capitalization$119.86 millionP/E Ratio-8.65Dividend YieldN/ABeta2.48 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and other preclinical product candidates, such as interleukin 2, a therapy for metastatic melanoma and renal cell carcinoma, as well as anti-parathyroid receptor to address unmet medical needs. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration and licensing agreements with Novartis AG; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Emeryville, California. Receive XOMA News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:XOMA Previous Symbol CUSIP98419J10 CIK791908 Webwww.xoma.com Phone510-204-7200Debt Debt-to-Equity Ratio1.15 Current Ratio8.35 Quick Ratio8.35Price-To-Earnings Trailing P/E Ratio-8.65 Forward P/E Ratio-10.50 P/E GrowthN/A Sales & Book Value Annual Sales$5.30 million Price / Sales22.62 Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book6.14Profitability EPS (Most Recent Fiscal Year)($1.59) Net Income$-13,340,000.00 Net Margins-251.80% Return on Equity-175.48% Return on Assets-27.45%Miscellaneous Employees13 Outstanding Shares8,711,000Market Cap$119.86 million Next Earnings Date5/8/2019 (Estimated) OptionableNot Optionable XOMA (NASDAQ:XOMA) Frequently Asked Questions What is XOMA's stock symbol? XOMA trades on the NASDAQ under the ticker symbol "XOMA." How were XOMA's earnings last quarter? XOMA Corp (NASDAQ:XOMA) issued its earnings results on Thursday, March, 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.14. The biotechnology company earned $1.69 million during the quarter, compared to the consensus estimate of $1.30 million. XOMA had a negative net margin of 251.80% and a negative return on equity of 175.48%. View XOMA's Earnings History. When is XOMA's next earnings date? XOMA is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for XOMA. What price target have analysts set for XOMA? 3 analysts have issued 12-month target prices for XOMA's stock. Their predictions range from $16.26 to $36.00. On average, they expect XOMA's share price to reach $26.0867 in the next year. This suggests a possible upside of 89.6% from the stock's current price. View Analyst Price Targets for XOMA. What is the consensus analysts' recommendation for XOMA? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XOMA. What are Wall Street analysts saying about XOMA stock? Here are some recent quotes from research analysts about XOMA stock: 1. According to Zacks Investment Research, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. " (3/9/2019) 2. HC Wainwright analysts commented, "Valuation disconnect continues even when considering a limited set of current assets. Regarding our valuation of XOMA we believe that the current share price is currently disconnected from the underlying value of even just its opportunity from Novartis (NVS; not rated) partnered assets, led by canakinumab (Ilaris)." (9/21/2018) Has XOMA been receiving favorable news coverage? News coverage about XOMA stock has trended positive on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. XOMA earned a news sentiment score of 2.3 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days. Who are some of XOMA's key competitors? Some companies that are related to XOMA include Assembly Biosciences (ASMB), Dynavax Technologies (DVAX), Kalvista Pharmaceuticals (KALV), Zymeworks (ZYME), BioSpecifics Technologies (BSTC), CytomX Therapeutics (CTMX), ZEALAND PHARMA/S (ZEAL), Corbus Pharmaceuticals (CRBP), Flexion Therapeutics (FLXN), Five Prime Therapeutics (FPRX), Akebia Therapeutics (AKBA), Corium International (CORI), Cytokinetics (CYTK), Innate Pharma (IPHYF) and AMAG Pharmaceuticals (AMAG). What other stocks do shareholders of XOMA own? Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Uranium Energy (UEC), Opko Health (OPK), Gilead Sciences (GILD), ZIOPHARM Oncology (ZIOP), Sarepta Therapeutics (SRPT) and Novavax (NVAX). Who are XOMA's key executives? XOMA's management team includes the folowing people: Mr. James R. Neal, CEO & Director (Age 63)Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 45)Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 43)Dr. Deepshikha Datta, Chief Bus. Officer Who are XOMA's major shareholders? XOMA's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.06%), Opaleye Management Inc. (4.77%), Fosun International Ltd (3.77%), Geode Capital Management LLC (1.00%), Geode Capital Management LLC (1.00%) and Northern Trust Corp (1.00%). Company insiders that own XOMA stock include Bvf Partners L P/Il, James R Neal, John Varian, Ness W Denman Van, Thomas M Burns and Value Fund L P Biotechnology. View Institutional Ownership Trends for XOMA. Which major investors are selling XOMA stock? XOMA stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Geode Capital Management LLC, Geode Capital Management LLC and ClariVest Asset Management LLC. Company insiders that have sold XOMA company stock in the last year include James R Neal, Ness W Denman Van and Thomas M Burns. View Insider Buying and Selling for XOMA. Which major investors are buying XOMA stock? XOMA stock was bought by a variety of institutional investors in the last quarter, including Fosun International Ltd, Opaleye Management Inc., BlackRock Inc., Chicago Equity Partners LLC, Northern Trust Corp, Bank of New York Mellon Corp, Two Sigma Advisers LP and Macquarie Group Ltd.. Company insiders that have bought XOMA stock in the last two years include Bvf Partners L P/Il, James R Neal and Value Fund L P Biotechnology. View Insider Buying and Selling for XOMA. How do I buy shares of XOMA? Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is XOMA's stock price today? One share of XOMA stock can currently be purchased for approximately $13.76. How big of a company is XOMA? XOMA has a market capitalization of $119.86 million and generates $5.30 million in revenue each year. The biotechnology company earns $-13,340,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. XOMA employs 13 workers across the globe. What is XOMA's official website? The official website for XOMA is http://www.xoma.com. How can I contact XOMA? XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected] MarketBeat Community Rating for XOMA (NASDAQ XOMA)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 343 (Vote Outperform)Underperform Votes: 321 (Vote Underperform)Total Votes: 664MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe XOMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/20/2019 by MarketBeat.com StaffFeatured Article: Are FAANG stocks a good investment?